Literature DB >> 17708543

Prognostic factors determining survival in differentiated thyroid cancer.

Mehmet Ali Gulcelik1, Nese Ersoz Gulcelik, Bekir Kuru, Mithat Camlibel, Haluk Alagol.   

Abstract

BACKGROUND: Differentiated thyroid cancer (DTC) is among the most curable cancers. We evaluated the prognoses of patients with DTC from an iodine-deficient area.
MATERIALS AND METHODS: Four hundred twenty-two patients with thyroid cancer who underwent surgery between 1992 and 2000 at the Ankara Oncology Hospital were evaluated. Three hundred eighty-two patients with DTC were included. Gender, age, histopathological type, tumor size, capsular invasion and vascular invasion, distant metastasis, TNM, and AMES-MACIS scoring were analyzed.
RESULTS: The 10-year disease-free survival rate was 72% and the overall survival rate was 88%. Age >/=45 years at presentation, follicular thyroid cancer, tumor extension beyond the thyroid capsule, vascular invasion, distant metastasis, increasing tumor size, stage, and high MACIS-AMES scores were found to be statistically significant adverse prognostic factors in univariate analysis for DFS and OAS. Multivariate analysis for DFS and OAS confirmed that distant metastasis, follicular thyroid cancer, tumor extension beyond the thyroid capsule, vascular invasion, primary tumor size, TNM stage, and high MACIS score were independent prognostic factors.
CONCLUSION: In DTC patients, in addition to traditional risk factors, prognostic factors, such as vascular invasion and capsular invasion, need to be evaluated; not only for achieving an adequate therapeutic approach, but also for avoiding overtreatment of low-risk patients.

Entities:  

Mesh:

Year:  2007        PMID: 17708543     DOI: 10.1002/jso.20845

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

1.  [Current TNM system of the UICC/AJCC : the prognostic significance for differentiated thyroid carcinoma].

Authors:  M Stratmann; C Sekulla; H Dralle; M Brauckhoff
Journal:  Chirurg       Date:  2012-07       Impact factor: 0.955

Review 2.  Thyroid hormone therapy in differentiated thyroid cancer.

Authors:  Giorgio Grani; Valeria Ramundo; Antonella Verrienti; Marialuisa Sponziello; Cosimo Durante
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

3.  Current concepts and future directions in differentiated thyroid cancer.

Authors:  Donald S A McLeod
Journal:  Clin Biochem Rev       Date:  2010-02

4.  Modeling follicular thyroid cancer for future therapies.

Authors:  Xuguang Zhu; Sheue-Yann Cheng
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

5.  Adequacy of pathology reports of specimens from patients with differentiated thyroid cancer.

Authors:  Ma Luisa Isidro; Gloria Lugo; Olga Fidalgo; Sara García-Arias
Journal:  Endocr Pathol       Date:  2012-12       Impact factor: 3.943

6.  The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.

Authors:  E M Triviño Ibáñez; M A Muros; E Torres Vela; J M Llamas Elvira
Journal:  Endocrine       Date:  2015-07-30       Impact factor: 3.633

7.  Prognostic values of thyroid tumours.

Authors:  Suzana Manxhuka-Kerliu; Emine Devolli-Disha; Arsim Gerxhaliu; Halil Ahmetaj; Arijeta Baruti; Sadushe Loxha; Hajdin Thaqi
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

8.  Factors Affecting Life Expectancy After Bone Metastasis in Adults - Results of a 5-year Prospective Study.

Authors:  Balaji Zacharia; Jerin Joy; Dhiyaneswaran Subramaniam; Puneeth Katapadi Pai
Journal:  Indian J Surg Oncol       Date:  2021-08-30

9.  Morbidity and long-term survival in patients with cervical re-exploration for papillary thyroid carcinoma.

Authors:  Nenia Baerbock; Anke Mittelstädt; Joachim Jähne
Journal:  Innov Surg Sci       Date:  2019-03-27

10.  Herpes and polyoma family viruses in thyroid cancer.

Authors:  Dimitris P Stamatiou; Stavros P Derdas; Odysseas L Zoras; Demetrios A Spandidos
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.